Bristol Glucophage XR Gets 35% Of New Rxs From Metformin Switches
Executive Summary
Bristol-Myers Squibb's Glucophage XR extended-release metformin for type 2 diabetes is getting 35% of its new prescriptions from patients switching off the company's immediate-release Glucophage, Bristol President-Worldwide Medicines Group Richard Lane told a Jan. 24 conference call.
You may also be interested in...
Bristol Repositions Glucovance, Glucophage XR As Metformin Generics Loom
A money-back guarantee will be part of Bristol-Myers Squibb's repositioning efforts for the metformin line extensions Glucophage XR and Glucovance.
MaxiPost-mortem
Second Phase III trial of stroke therapy MaxiPost "showed no significant difference in the overall efficacy and safety or tolerability between MaxiPost and placebo," Bristol reports. The first trial similarly failed to show evidence of benefit (1"The Pink Sheet" Jan. 29, p. 22). "We are now in the process of analyzing the data a little further, and we are going to review our options after that"
Bristol Repositions Glucovance, Glucophage XR As Metformin Generics Loom
A money-back guarantee will be part of Bristol-Myers Squibb's repositioning efforts for the metformin line extensions Glucophage XR and Glucovance.